The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Psychiatry

• Publication date

  2009-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/appi.ajp.2009.09010017PMID 19570929PMCID PMC3735363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.

  2009cited by this paper
• Temporal relationship between change in cognition and change in functioning in schizophrenia.

  2008cited by this paper
• A synaptic memory trace for cortical receptive field plasticity

  2007cited by this paper
• How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia.

  2007cited by this paper
• Focusing Effect of Acetylcholine on Neuroplasticity in the Human Motor Cortex

  2007cited by this paper
• Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia.

  2006cited by this paper
• Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain.

  2006cited by this paper
• A model of anticholinergic activity of atypical antipsychotic medications.

  2006cited by this paper
• Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans.

  2005cited by this paper
• Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection.

  2005cited by this paper
• Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia.

  2005cited by this paper
• Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans.

  2005cited by this paper
• Serum anticholinergic activity, white matter hyperintensities, and cognitive performance

  2005cited by this paper
• Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.

  2004cited by this paper
• Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model.

  2004cited by this paper
• Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.

  2004cited by this paper
• Cholinergic modulation of visual attention and working memory: dissociable effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal infusions of scopolamine.

  2004cited by this paper
• Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment.

  2003cited by this paper
• Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance.

  2003cited by this paper
• Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine.

  2003cited by this paper
• Selective immunolesioning of the basal forebrain cholinergic neurons in rats: effect on attention using the 5-choice serial reaction time task

  2002cited by this paper
• Selective Behavioral and Neurochemical Effects of Cholinergic Lesions Produced by Intrabasalis Infusions of 192 IgG-Saporin on Attentional Performance in a Five-Choice Serial Reaction Time Task

  2002cited by this paper
• Anticholinergicity and cognitive processing in chronic schizophrenia.

  2001cited by this paper
• Practice-related improvement in information processing with novel antipsychotic treatment.

  2000cited by this paper
• Cortical map reorganization enabled by nucleus basalis activity.

  1998cited by this paper
• Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline.

  1998cited by this paper
• Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients.

  1997cited by this paper
• Selective Immunolesioning of the Basal Forebrain Cholinergic System Disrupts Short‐term Memory in Rats

  1996cited by this paper
• Effects of anticholinergic medication on memory in schizophrenia.

  1990cited by this paper
• Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

  1989cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987influential reference
• Memory deficits and anticholinergic levels in chronic schizophrenia.

  1986cited by this paper
• Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.

  1982cited by this paper
• Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.

  1980cited by this paper

• Cognitive function at first episode in patients subsequently developing treatment-resistant schizophrenia.

  2025cites this paper
• Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations.

  2025cites this paper
• Why Not Rock the Boat? Deprescribing Anticholinergic Medications That Are No Longer Needed in Persons With Schizophrenia.

  2025cites this paper
• Cognitive remediation for patients with late-life schizophrenia: A follow-up pilot study.

  2025cites this paper
• Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission.

  2025cites this paper
• Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide

  2025cites this paper
• Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Effects of Computerized Cognitive Training on Vesicular Acetylcholine Transporter Levels using [18F]Fluoroethoxybenzovesamicol Positron Emission Tomography in Healthy Older Adults: Results from the Improving Neurological Health in Aging via Neuroplasticity-based Computerized Exercise (INHANCE) Rando

  2025cites this paper
• Formulating Cognitive Functioning to Guide Personalised Treatment for People Diagnosed With Mental Disorders

  2025cites this paper
• Anticholinergic Burden in Serious Mental Illness: Is This a Plague Hiding in Plain Sight?

  2025cites this paper
• Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study.

  2025cites this paper
• Eye movements as predictor of cognitive improvement after cognitive remediation therapy in patients with schizophrenia.

  2024cites this paper
• Personalized Cognitive Health in Psychiatry: Current State and the Promise of Computational Methods.

  2024cites this paper
• Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology.

  2024cites this paper
• Cognitive impairment and functional outcomes in schizophrenia: a narrative review

  2024cites this paper
• The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study.

  2024cites this paper
• Efficacy and safety of prophylactic use of benzhexol after risperidone treatment in MK-801-induced mouse model of schizophrenia

  2024cites this paper
• Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations

  2024cites this paper
• Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives

  2024cites this paper
• An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders

  2024cites this paper
• Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment?

  2024cites this paper
• Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.

  2024cites this paper
• Identification and treatment of individuals with childhood-onset and early-onset schizophrenia.

  2024cites this paper
• Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives

  2024cites this paper
• Conceptualization and characterization of "primary" and "secondary" cognitive impairment in schizophrenia.

  2024cites this paper
• Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia.

  2024cites this paper
• Harnessing neuroplasticity.

  2023cites this paper
• The Prognostic Utility of Anticholinergic Burden Scales: An Integrative Review and Gap Analysis

  2023cites this paper
• Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapy

  2023cites this paper
• Cognitive Rehabilitation for Patients with Schizophrenia: A Narrative Review of Moderating Factors, Strategies, and Outcomes.

  2023cites this paper
• Behavioral Health Emergencies

  2023cites this paper
• Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden.

  2023cites this paper
• Medication impact on oral health in schizophrenia

  2023cites this paper
• Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia

  2023cites this paper
• Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system

  2023cites this paper
• Mismatch negativity predicts initial auditory-based targeted cognitive training performance in a heterogeneous population across psychiatric disorders.

  2023cites this paper
• Effects of Anticholinergic Burden on Verbal Memory Performance in First-Episode Psychosis

  2023cites this paper
• Gender Difference in Cognitive Function Among Stable Schizophrenia: A Network Perspective

  2022cites this paper
• Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity

  2022cites this paper
• Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature

  2022cites this paper
• Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital

  2022cites this paper
• Advances in Cognitive Remediation Training in Schizophrenia: A Review

  2022influential citation
• Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia

  2022cites this paper
• Management of cognitive and negative symptoms in schizophrenia

  2022cites this paper
• European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia

  2022cites this paper
• Considering medication exposure in genomic association studies of cognition in psychotic disorders.

  2022cites this paper
• Efficacy of technology-based interventions in psychosis: a systematic review and network meta-analysis

  2022cites this paper
• Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.

  2022cites this paper
• Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course

  2021cites this paper
• The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection

  2021cites this paper
• Less is more: Deprescribing anticholinergic medications in persons with severe mental illness.

  2021cites this paper
• Video games for people with schizophrenia.

  2021cites this paper
• Long-acting injectable antipsychotics: what, when, and how

  2021cites this paper
• Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics.

  2021cites this paper
• Strategies for Psychiatric Rehabilitation and their Cognitive Outcomes in Schizophrenia: Review of Last Five-year Studies

  2021cites this paper
• Durable Cognitive Gains and Symptom Improvement Are Observed in Individuals With Recent-Onset Schizophrenia 6 Months After a Randomized Trial of Auditory Training Completed Remotely.

  2021cites this paper
• Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.

  2021cites this paper
• Less is more: Deprescribing anticholinergic medications in persons with severe mental illness.

  2021cites this paper
• Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction.

  2021cites this paper
• Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults.

  2021cites this paper
• Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review

  2021influential citation
• Treatment of Tardive Dyskinesia.

  2020cites this paper
• Effect of Non-Computerized Cognitive Remediation and Risperidone to Improve Disability Function in Schizophrenia

  2020cites this paper
• Predictors of response to cognitive remediation in patients with major psychotic disorders: A narrative review.

  2020cites this paper
• Intervention-specific patterns of cortical function plasticity during auditory encoding in people with schizophrenia.

  2020cites this paper
• Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks

  2020cites this paper
• Maintenance phase treatment of psychotic disorders in outpatients from Serbia – focus on long-term benzodiazepine use

  2020cites this paper
• Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia

  2020cites this paper
• Neurocognition and Treatment Outcomes in Schizophrenia

  2020cites this paper
• The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span.

  2020cites this paper
• Neuregulin 3 rs10748842 polymorphism contributes to the effect of body mass index on cognitive impairment in patients with schizophrenia

  2020cites this paper
• Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers

  2020influential citation
• Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement.

  2020cites this paper
• Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study

  2019cites this paper
• A systematic review of moderators of cognitive remediation response for people with schizophrenia

  2019cites this paper
• NDT_A_205933 2195..2203

  2019cites this paper
• The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia.

  2019cites this paper
• A randomized controlled trial comparing a "bottom-up" and "top-down" approach to cognitive training in schizophrenia.

  2019cites this paper
• Title : European Psychiatric Association ( EPA ) guidance on forensic psychiatry : Evidence based assessment and treatment of mentally disordered offenders

  2019cites this paper
• Neural changes following cognitive remediation therapy for schizophrenia

  2019influential citation
• Mismatch negativity reveals plasticity in cortical dynamics after 1-hour of auditory training exercises.

  2019cites this paper
• A systematic review of factors that influence the efficacy of cognitive remediation therapy in schizophrenia

  2019cites this paper
• Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia?

  2019cites this paper
• Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research.

  2019cites this paper
• Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.

  2019cites this paper
• Factors Associated With Response and Resistance to Cognitive Remediation in Schizophrenia: A Critical Review

  2019cites this paper
• Sensory-targeted cognitive training for schizophrenia

  2019cites this paper
• The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy

  2019cites this paper
• Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients.

  2019influential citation
• The effects of cognitive remediation on cognitive abilities and real-world functioning among people with bipolar disorder: A systematic review.

  2019cites this paper
• Dysregulation of auditory neuroplasticity in schizophrenia.

  2019cites this paper
• Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia.

  2019cites this paper
• The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.

  2019cites this paper
• Neurocognitive and Self-efficacy Benefits of Cognitive Remediation in Schizophrenia: A Randomized Controlled Trial

  2018cites this paper
• Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

  2018cites this paper
• Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

  2018cites this paper
• Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy

  2018cites this paper
• Serum anticholinergicity is associated with reduced prefrontal brain function in early course schizophrenia.

  2018cites this paper
• Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care.

  2018cites this paper
• Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management

  2018cites this paper